Olink® Target 48 platform now available
Offering scalable multiplexing while preserving sensitivity and specificity
Rules-Based Medicine now offers immunoassay services on the Olink Target platform. The Target 48 Cytokine Panel is comprised of 45 proteins measured quantitatively in a single multiplex using 1 µL of sample. These cytokines are associated with inflammation and immune system regulation, demonstrating utility across several therapeutic research areas, including autoimmune, oncology, immuno-oncology, neurology, and cardiovascular disease.
Exceptional Science
- The Olink proximity extension assay (PEA) technology employs a dual-recognition approach using antibody pairs labeled with complimentary DNA oligonucleotides. When the antibody pair binds to the target protein, the oligonucleotides are in proximity and hybridize, creating a unique barcode. This DNA barcode is extended, amplified by polymerase chain reaction (PCR), and measured by quantitative PCR (qPCR). PEA provides enhanced sensitivity and specificity, as mismatched oligonucleotides do not hybridize to form a barcode, and, thus, no signal will be generated.
- The Target 48 Cytokine Panel contains both internal and external quality controls (QC). Internal controls monitor performance of the PEA reaction steps and data normalization. The external controls consist of Sample Control, Negative Control and Calibrator.
Service Excellence
- RBM is an Olink Target platform Service Provider, offering customers the flexibility to choose the Target 48 panel, or to choose their preferred analytes using the custom Flex or Focus products. Contact RBM for product availability.
| Target 48 Cytokine Panel (additional panels forthcoming ) | ||
| C-C motif chemokine 2 (CCL2) | Interferon gamma (IFNG) | Interleukin-33 (IL33) |
| C-C motif chemokine 3 (CCL3) | Interleukin-1 beta (IL1B) | Interstitial collagenase (MMP1) |
| C-C motif chemokine 4 (CCL4) | Interleukin-2 (IL2) | Lymphotoxin-alpha (LTA) |
| C-C motif chemokine 7 (CCL7) | Interleukin-4 (IL4) | Macrophage colony-stimulating factor 1 (CSF1) |
| C-C motif chemokine 8 (CCL8) | Interleukin-6 (IL6) | Macrophage metalloelastase (MMP12) |
| C-X-C motif chemokine 9 (CXCL9) | Interleukin-7 (IL7) | Oncostatin-M (OSM) |
| C-X-C motif chemokine 10 (CXCL10) | Interleukin-8 (CXCL8) | Oxidized low-density lipoprotein receptor 1 (OLR1) |
| C-X-C motif chemokine 11 (CXCL11) | Interleukin-10 (IL10) | Pro-epidermal growth factor (EGF) |
| C-C motif chemokine 13 (CCL13) | Interleukin-13 (IL13) | Protransforming growth factor alpha (TGFA) |
| C-C motif chemokine 19 (CCL19) | Interleukin-15 (IL15) | Stromal cell-derived factor 1 (CXCL12) |
| Eotaxin (CCL11) | Interleukin-17A (IL17A) | Thymic stromal lymphopoietin (TSLP) |
| Fms-related tyrosine kinase 3 ligand (FLT3LG) | Interleukin-17C (IL17C) | Tumor necrosis factor (TNF) |
| Granulocyte-macrophage colony-stimulating factor (CSF2) | Interleukin-17F (IL17F) | Tumor necrosis factor ligand superfamily member 10 (TNFSF10) |
| Granulocyte colony-stimulating factor (CSF3) | Interleukin-18 (IL18) | Tumor necrosis factor ligand superfamily member 12 (TNFSF12) |
| Hepatocyte growth factor (HGF) | Interleukin-27 (EBI3_IL27) | Vascular endothelial growth factor A (VEGFA) |
Sample requirement: 1 aliquot of 40 µL plasma for Target 48 only. Call client services for sample requirements when requesting Olink in addition to other platforms.
The addition of Olink expands Rules-Based Medicine’s ability to support customers in understanding complex mechanisms of action throughout the development pipeline from therapeutic area-based discovery to custom Flex or Focus panels.
